Literature DB >> 15059942

Point-counterpoint of sphingosine 1-phosphate metabolism.

Julie D Saba1, Timothy Hla.   

Abstract

Sphingosine 1-phosphate (S1P), an evolutionarily conserved bioactive lipid mediator, is now recognized as a potent modulator of cell regulation. In vertebrates, S1P interacts with cell surface G protein-coupled receptors of the EDG family and induces profound effects in a variety of organ systems. Indeed, an S1P receptor agonist is undergoing clinical trials to combat immune-mediated transplant rejection. Recent information on S1P receptor biology suggests potential utility in the control of cardiovascular processes, including angiogenesis, vascular permeability, arteriogenesis, and vasospasm. However, studies from diverse invertebrates, such as yeast, Dictyostelium, Drosophila, and Caenorhabditis elegans have shown that S1P is involved in important regulatory functions in the apparent absence of EDG S1P receptor homologues. Metabolic pathways of S1P synthesis, degradation, and release have recently been described at the molecular level. Genetic and biochemical studies of these enzymes have illuminated the importance of S1P signaling systems both inside and outside of cells. The revelation of receptor-dependent pathways, as well as novel metabolic/intracellular pathways has provided new biological insights and may ultimately pave the way for the development of novel therapeutic approaches for cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059942     DOI: 10.1161/01.RES.0000122383.60368.24

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  97 in total

Review 1.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Sphingosine-1-phosphate prevents permeability increases via activation of endothelial sphingosine-1-phosphate receptor 1 in rat venules.

Authors:  Gengqian Zhang; Sulei Xu; Yan Qian; Pingnian He
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-08-20       Impact factor: 4.733

Review 3.  Regulation and functional roles of sphingosine kinases.

Authors:  Regina Alemany; Chris J van Koppen; Kerstin Danneberg; Michael Ter Braak; Dagmar Meyer Zu Heringdorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-23       Impact factor: 3.000

4.  Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins.

Authors:  J Igarashi; M Miyoshi; T Hashimoto; Y Kubota; H Kosaka
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

5.  Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors.

Authors:  Puneet S Jolly; Meryem Bektas; Kenneth R Watterson; Heidi Sankala; Shawn G Payne; Sheldon Milstien; Sarah Spiegel
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

6.  Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina.

Authors:  Athanasia Skoura; Teresa Sanchez; Kevin Claffey; Suzanne M Mandala; Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference.

Authors:  Sung-Suk Chae; Ji-Hye Paik; Henry Furneaux; Timothy Hla
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 8.  The role of sphingosine-1-phosphate and its receptors in asthma.

Authors:  John J Ryan; Sarah Spiegel
Journal:  Drug News Perspect       Date:  2008-03

Review 9.  Cross-talk at the crossroads of sphingosine-1-phosphate, growth factors, and cytokine signaling.

Authors:  Deborah A Lebman; Sarah Spiegel
Journal:  J Lipid Res       Date:  2008-04-02       Impact factor: 5.922

Review 10.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.